212 related articles for article (PubMed ID: 28712706)
21. A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition.
Redenti S; Marcovich I; De Vita T; Pérez C; De Zorzi R; Demitri N; Perez DI; Bottegoni G; Bisignano P; Bissaro M; Moro S; Martinez A; Storici P; Spalluto G; Cavalli A; Federico S
ChemMedChem; 2019 Feb; 14(3):310-314. PubMed ID: 30548443
[TBL] [Abstract][Full Text] [Related]
22. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
Mohammad MK; Al-Masri IM; Taha MO; Al-Ghussein MA; Alkhatib HS; Najjar S; Bustanji Y
Eur J Pharmacol; 2008 Apr; 584(1):185-91. PubMed ID: 18295757
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of novel 4,5-bisindolyl-1,2,4-triazol-3-ones as glycogen synthase kinase-3β inhibitors and neuroprotective agents.
Hu Y; Ruan W; Gao A; Zhou Y; Gao L; Xu M; Gao J; Ye Q; Li J; Pang T
Pharmazie; 2017 Dec; 72(12):707-713. PubMed ID: 29441954
[TBL] [Abstract][Full Text] [Related]
24. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3β Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones.
Liang Z; Li QX
ACS Chem Neurosci; 2018 May; 9(5):1166-1183. PubMed ID: 29381861
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors.
Arfeen M; Bhagat S; Patel R; Prasad S; Roy I; Chakraborti AK; Bharatam PV
Eur J Med Chem; 2016 Oct; 121():727-736. PubMed ID: 27423119
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of 3-benzisoxazolyl-4-indolylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3β.
Ye Q; Li M; Zhou Y; Pang T; Xu L; Cao J; Han L; Li Y; Wang W; Gao J; Li J
Molecules; 2013 May; 18(5):5498-516. PubMed ID: 23669633
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
[TBL] [Abstract][Full Text] [Related]
29. Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3β inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues.
Han S; Zhou W; Zhuang C; Chen F
Bioorg Chem; 2022 Feb; 119():105537. PubMed ID: 34902644
[TBL] [Abstract][Full Text] [Related]
30. Amaryllidaceae Alkaloids as Potential Glycogen Synthase Kinase-3β Inhibitors.
Hulcová D; Breiterová K; Siatka T; Klímová K; Davani L; Šafratová M; Hošťálková A; De Simone A; Andrisano V; Cahlíková L
Molecules; 2018 Mar; 23(4):. PubMed ID: 29561817
[TBL] [Abstract][Full Text] [Related]
31. Discovery of potent and bioavailable GSK-3beta inhibitors.
Gong L; Hirschfeld D; Tan YC; Heather Hogg J; Peltz G; Avnur Z; Dunten P
Bioorg Med Chem Lett; 2010 Mar; 20(5):1693-6. PubMed ID: 20138512
[TBL] [Abstract][Full Text] [Related]
32. Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation.
Mohammad M; Al-Masri IM; Issa A; Al-Ghussein MA; Fararjeh M; Alkhatib H; Taha MO; Bustanji Y
J Enzyme Inhib Med Chem; 2013 Aug; 28(4):690-4. PubMed ID: 22512725
[TBL] [Abstract][Full Text] [Related]
33. Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors.
Gentile G; Bernasconi G; Pozzan A; Merlo G; Marzorati P; Bamborough P; Bax B; Bridges A; Brough C; Carter P; Cutler G; Neu M; Takada M
Bioorg Med Chem Lett; 2011 Aug; 21(16):4823-7. PubMed ID: 21764580
[TBL] [Abstract][Full Text] [Related]
34. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability.
Saitoh M; Kunitomo J; Kimura E; Iwashita H; Uno Y; Onishi T; Uchiyama N; Kawamoto T; Tanaka T; Mol CD; Dougan DR; Textor GP; Snell GP; Takizawa M; Itoh F; Kori M
J Med Chem; 2009 Oct; 52(20):6270-86. PubMed ID: 19775160
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Jiang X; Wang Y; Liu C; Xing C; Wang Y; Lyu W; Wang S; Li Q; Chen T; Chen Y; Feng F; Liu W; Sun H
Bioorg Med Chem; 2021 Jan; 30():115940. PubMed ID: 33340937
[TBL] [Abstract][Full Text] [Related]
36. The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.
Khanfar MA; Asal BA; Mudit M; Kaddoumi A; El Sayed KA
Bioorg Med Chem; 2009 Aug; 17(16):6032-9. PubMed ID: 19616957
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease.
Shi XL; Wu JD; Liu P; Liu ZP
Eur J Med Chem; 2019 Apr; 167():211-225. PubMed ID: 30772605
[TBL] [Abstract][Full Text] [Related]
38. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
[TBL] [Abstract][Full Text] [Related]
39. Discovery of novel quinolin-2-one derivatives as potential GSK-3β inhibitors for treatment of Alzheimer's disease: Pharmacophore-based design, preliminary SAR, in vitro and in vivo biological evaluation.
Abdo Moustafa E; Abdelrasheed Allam H; Fouad MA; El Kerdawy AM; Nasser Eid El-Sayed N; Wagner C; Abdel-Aziz HA; Abdel Fattah Ezzat M
Bioorg Chem; 2024 May; 146():107324. PubMed ID: 38569322
[TBL] [Abstract][Full Text] [Related]
40. Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.
Miyazaki Y; Maeda Y; Sato H; Nakano M; Mellor GW
Bioorg Med Chem Lett; 2008 Mar; 18(6):1967-71. PubMed ID: 18280153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
